Page last updated: 2024-12-11

novolimus

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

novolimus: belongs to the family of macrocyclic lactones with immunosuppressive and anti-proliferative properties [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9854320
CHEMBL ID3544688
SCHEMBL ID7715643
MeSH IDM0529101

Synonyms (22)

Synonym
7-o-demethyl rapamycin
7-o-demethyl rapammune
151519-50-5
7-o-demethyl cypher
CJ-12263 ,
SCHEMBL7715643
unii-2719uahua8
16-o-demethylsirolimus
CHEMBL3544688
rapamycin, 7-o-demethyl-
HY-123691
CS-0084352
7-o-demethylrapamycin
16-o-demethylrapamycin
novolimus
n-929-89b
2719UAHUA8 ,
7-o-demethylsirolimus
cj12263
cj 12263
novolimus (80%)
7-o-demethyl rapamycin (~80%)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"In this FIM study, implantation of the novolimus-eluting stent was proven to be feasible, safe and elicited minimum neointimal proliferation."( EXCELLA First-in-Man (FIM) study: safety and efficacy of novolimus-eluting stent in de novo coronary lesions.
Abizaid, A; Bhat, V; Costa, JR; Costa, R; Feres, F; Fitzgerald, P; Maia, F; Meredith, L; Ormiston, J; Seixas, AC; Siqueira, D; Sousa, AG; Sousa, JE; Staico, R; Tanajura, LF; Yan, J, 2008
)
0.86
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (3.70)29.6817
2010's22 (81.48)24.3611
2020's4 (14.81)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.90 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index5.79 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (17.86%)5.53%
Reviews3 (10.71%)6.00%
Case Studies3 (10.71%)4.05%
Observational1 (3.57%)0.25%
Other16 (57.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]